{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:05:51Z","timestamp":1793862351029,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jchf.2024.04.027","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T18:49:46Z","timestamp":1718822986000},"page":"1442-1455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Low Natriuretic Peptide Levels and Outcomes in Patients With Heart\u00a0Failure and Preserved Ejection Fraction"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-7574","authenticated-orcid":false,"given":"Toru","family":"Kondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.04.027_bib1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jchf.2024.04.027_bib2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.027_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ejhf.2601","volume":"24","author":"Guazzi","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib5","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/eurheartj\/ehac121","article-title":"BNP: biomarker not perfect in heart failure with preserved ejection fraction","volume":"43","author":"Shah","year":"2022","journal-title":"Eu Heart J"},{"key":"10.1016\/j.jchf.2024.04.027_bib6","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.04.027_bib7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2012.05.014","article-title":"Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction","volume":"110","author":"Anjan","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.04.027_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12471-016-0816-8","article-title":"Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides","volume":"24","author":"Meijers","year":"2016","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jchf.2024.04.027_bib9","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.027_bib10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cardfail.2005.06.432","article-title":"The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design","volume":"11","author":"Carson","year":"2005","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF Trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib13","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.027_bib14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with hf with mildly reduced and preserved ejection fraction: DELIVER Trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.027_bib17","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart\u00a0Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.04.027_bib18","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.027_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.echo.2008.11.023","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"22","author":"Nagueh","year":"2009","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2024.04.027_bib20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2024.04.027_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.amjcard.2005.07.126","article-title":"Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons > or =65 years of age (the cardiovascular health study)","volume":"97","author":"Gottdiener","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.04.027_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0002-8703(92)90986-6","article-title":"Am Assessment of patient outcome with the Minnesota Living with Heart\u00a0Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan","volume":"124","author":"Rector","year":"1992","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2024.04.027_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2008.03.081","article-title":"Patterns of structural and functional remodeling of the left ventricle in chronic heart failure","volume":"102","author":"Gaasch","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.04.027_bib24","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.105.573865","article-title":"Matrix metalloproteinases\/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease","volume":"113","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.027_bib25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0894-7317(03)00516-9","article-title":"Association of newer diastolic function parameters with age in healthy subjects: a population-based study","volume":"16","author":"Munagala","year":"2003","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jchf.2024.04.027_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cardfail.2021.12.007","article-title":"Under-enrollment of obese heart failure with preserved ejection fraction patients in major HFpEF clinical trials","volume":"28","author":"Vaishnav","year":"2022","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ehf2.12235","article-title":"Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction","volume":"5","author":"Buckley","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.pcad.2020.09.006","article-title":"Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure","volume":"63","author":"Singh","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jchf.2024.04.027_bib29","first-page":"100","article-title":"Heart failure with preserved ejection fraction - unwinding the diagnosis mystique","volume":"4","author":"Asrar","year":"2014","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.jchf.2024.04.027_bib30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.hfc.2014.04.009","article-title":"Comorbidities and differential diagnosis in heart failure with preserved ejection fraction","volume":"10","author":"Campbell","year":"2014","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.jchf.2024.04.027_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.hfc.2014.04.010","article-title":"Diagnosis of heart failure with preserved ejection fraction","volume":"10","author":"Wachter","year":"2014","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.jchf.2024.04.027_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12170-011-0184-2","article-title":"Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma","volume":"5","author":"Bhuiyan","year":"2011","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.jchf.2024.04.027_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/CIRCULATIONAHA.121.058592","article-title":"Longitudinal evolution of cardiac dysfunction in heart failure and preserved ejection fraction with normal natriuretic peptide levels","volume":"146","author":"Sorimachi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.027_bib34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/PPA.S312200","article-title":"Burden and quality of life among female and male patients with heart failure in europe: a real-world cross-sectional study","volume":"15","author":"Fonseca","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jchf.2024.04.027_bib35","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/ehf2.12904","article-title":"The impact of pharmacist\/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial","volume":"7","author":"Schulz","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cardfail.2020.01.001","article-title":"Sex differences in exercise capacity and quality of life in heart failure with preserved ejection fraction: a secondary analysis of the RELAX and NEAT-HFpEF Trials","volume":"26","author":"Honigberg","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.1503","article-title":"Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial","volume":"21","author":"Schulz","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003878","article-title":"Accelerometer-measured daily activity in heart failure with preserved ejection fraction: clinical correlates and association with standard heart failure severity indices","volume":"10","author":"Snipelisky","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib39","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide mononitrate in heart failure with preserved ejection fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.027_bib40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2024.04.027_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cardfail.2004.11.004","article-title":"Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart\u00a0Failure Trial","volume":"11","author":"Majani","year":"2005","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib43","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011146","article-title":"Proteomic associations of NT-proBNP (N-terminal pro-B-type natriuretic peptide) in heart failure with preserved ejection fraction","volume":"17","author":"Azzo","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.027_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011428","article-title":"Ongoing enigma of NT-proBNP in HFpEF: insights from proteomics","volume":"17","author":"Myhre","year":"2024","journal-title":"Circ Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924004141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924004141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:48:29Z","timestamp":1726753709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924004141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2213177924004141"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.04.027","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Natriuretic Peptide Levels and Outcomes in Patients With Heart\u00a0Failure and Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}